| Identification | Back Directory | [Name]
L-Lysine, L-serylglycyl-L-glutaminyl-L-tyrosyl-L-alanyl-L-seryl-L-tyrosyl-L-histidyl-L-cysteinyl-L-tryptophyl-L-cysteinyl-L-tryptophyl-L-arginyl-L-α-aspartyl-L-prolylglycyl-L-arginyl-L-serylglycylglycyl-L-seryl- | [CAS]
2426685-25-6 | [Synonyms]
L-Lysine, L-serylglycyl-L-glutaminyl-L-tyrosyl-L-alanyl-L-seryl-L-tyrosyl-L-histidyl-L-cysteinyl-L-tryptophyl-L-cysteinyl-L-tryptophyl-L-arginyl-L-α-aspartyl-L-prolylglycyl-L-arginyl-L-serylglycylglycyl-L-seryl- | [Molecular Formula]
C107H150N34O32S2 | [MOL File]
2426685-25-6.mol | [Molecular Weight]
2488.7 |
| Hazard Information | Back Directory | [Uses]
TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function[1]. | [in vivo]
TPP-1 (subcutaneous injection; 4 mg/kg; every other day eight times; 32 days) inhibits tumor growth (compared with SPP-1 and control). The growth rate in TPP-1-treated mice is 56%. And when administered in the absence of T cells (control group), TPP-1 has no effect on the growth of the H460-luc tumors[1]. | Animal Model: | 5 to 6-week-old female Balb/c nude mice? injected with H460 cells transfected with the plvx-puro/luciferase lentiviral vector[1] | | Dosage: | 4 mg/kg | | Administration: | Subcutaneous injection; 4 mg/kg; every other day eight times; 32days | | Result: | Inhibited the tumor growth in a tumor xenograft model via reactivating T-cell function.? |
| [References]
[1] Chunlin Li, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018 Feb;6(2):178-188. DOI:10.1158/2326-6066.CIR-17-0035 |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 15083780366 |
| Website: |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|